Posts by Sandra Ansanay-Alex
19th Innovation Day at HUG: Meet the Winners!
At their 19th Innovation Day, the Geneva University Hospitals (HUG) highlighted 16 innovative projects from the hospital and academic sectors, grouped into three categories: Proof of Concept, Prototype, and Launch-Ready Product. Top 3 Awarded Projects: 🥇 Flow Twin: A 3D modeling platform of brain vessels for training, planning personalized endovascular procedures, and testing new…
Read MoreADC Therapeutics Announces $60 Million Private Placement
ADC Therapeutics SA, a Vaud-based commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private investment in public equity (“PIPE”) financing. In the PIPE, ADC Therapeutics…
Read MoreHealth.Tech Global Summit
The Health.Tech Global Summit is taking place from 3 to 5 March 2026 in Basel The health.tech Summit brings together global leaders, innovators, and visionaries at the forefront of healthcare transformation. Through expert guidance and collaboration, our event delivers groundbreaking insights, meaningful connections, and a future-focused vision for the industry. More than 5,000 participants…
Read MoreThe MAGNET: The Future of Cell & Gene Therapy
The Magnet, The Future of Cell & Gene Therapy event is taking place on 18 November 2025 in Allschwill Basel is emerging as a global hub for Cell & Gene Therapy (CGT), attracting major investment and cutting-edge research. Yet despite breakthroughs, the field faces challenges—from regulatory uncertainty to high expectations and fluctuating investment. Join…
Read MoreEIT Food Biotech Innovation Call
Apply before 17 November 2025 for the new EIT Food Biotech innovation call EIT Food is launching a call designed to boost high-potential innovations and help them reach commercialization. This funding opportunity is part of the EIT Food Co-financed Biotech Portfolio. This portfolio has identified two key industry challenges where we need to find innovative…
Read MoreRelief Therapeutics merges with NeuroX to form MindMaze Therapeutics
The new entity, valued at CHF 1.1 billion, is positioned as a leader in neurotechnology. The transaction is expected to close in December 2025. RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, and NeuroX Group SA (NeuroX), a privately held company focused on digital…
Read MorePrêt ? Partez, Pitch ! – The Finale
The finale of GENILEM’s contest, Prêt ? Partez, Pitch !, is taking place on 3 December 2025 at the Musée Olympique in Lausanne. PRÊT ? PARTEZ, PITCH ! was launched by GENILEM in 2020 to support and promote innovative entrepreneurship in our region! Through this competition, we highlight up-and-coming projects and give them the…
Read MoreFONGIT Life: What Life Sciences Investors Want
Lunch and learn! FONGIT Life event, What Life Sciences Investors Want, is taking place on 18 November 2025 at Campus Biotech Geneva Raising capital in life sciences comes with unique challenges—and opportunities. This interactive workshop brings together three experienced life sciences investors to share what they really look for in early-stage startups. Whether you’re…
Read MoreLICR, CHUV and UNIL extend their collaboration and renew their partnership
The Canton of Vaud, the Lausanne University Hospital (CHUV), the University of Lausanne (UNIL) and the Ludwig Institute for Cancer Research (LICR) have signed a new agreement. This agreement extends the presence of the Ludwig branch in Lausanne and strengthens their collaboration. This partnership has already attracted world-renowned scientists in the field of cancer. It…
Read MoreUCB Farchim Invests Over CHF 100 Million and Creates 80 New Jobs in Bulle
UCB Farchim, the Swiss subsidiary of Belgian biopharmaceutical group UCB, has announced a major new phase of development for its Bulle (Fribourg) site, with more than CHF 100 million in new investments and the creation of 80 additional jobs by 2030. Since opening in 1996, UCB has invested nearly CHF 700 million in its…
Read More